Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 3/20 | 0.38 |
| ▸ | CCND3 | P30281 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14428800 | 0.97 | MAPT (0.42) | AKT1SMN1; SMN2CA1CA2MAPT | |
| SCHEMBL14428565 | 0.93 | MAPK1 (0.37) | AKT1SMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL5400741 | 0.92 | AKT1 (0.44) | AKT1SMN1; SMN2CA1CA2MAPT | |
| SCHEMBL14440557 | 0.91 | MAPT (0.38) | AKT1SMN1; SMN2CA1CA2MAPT | |
| SCHEMBL5396837 | 0.89 | CA1 (0.43) | AKT1SMN1; SMN2CA1CA2MAPT | |
| SCHEMBL14428801 | 0.87 | CA1 (0.43) | SMN1; SMN2CA1CA2MAPTMEN1 | |
| SCHEMBL5380778 | 0.85 | MAPK1 (0.37) | AKT1CA1CA2MEN1ALDH1A1 | |
| SCHEMBL5396807 | 0.82 | EP300 (0.42) | SMN1; SMN2CA1CA2ALDH1A1CDK4 | |
| SCHEMBL5387709 | 0.81 | EP300 (0.41) | SMN1; SMN2CA1CA2MAPTALDH1A1 | |
| SCHEMBL5396855 | 0.80 | CA1 (0.45) | SMN1; SMN2CA1CA2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197533-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070197533-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197533-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | DDC, DPP3, AMPD3 | AKT1 4351/4885SMN1; SMN2 3797/4885CA1 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.